Upon conclusion of this program, participants should be able to:

1. New drugs for management of chronic lymphocytic leukemia patients

• Describe the two most recent drugs approved for use in CLL patients
• Recognize the side effects and dosing adjustments for these drugs

2. Impact of molecular  and cytogenetic risk stratefication in treatment decisions for acute leukemia patients including influence of age of the partient and using Minimal Residual Disease (MRD) monitoring:

• Recognize current molecular markers for Acute Myeloid Leukemia (AML) and their therapeutic implication.
• Demonstrate risk stratification of cytogenetics and age and their influence on therapy decisions
• Describe general principles of Acute Lymphoid Leukemia (ALL) management.

3.  Management of Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) patients  

• Assess when to start Hypomethylating agents (HMA) for MDS patients
• Demonstrate initial treatment choice for Polycythemia vera (PV), Essential thrombocytemia (ET), Myelofibrosis (MF) patients.
• Apply therapeutic decisions based on response assessment    

Attendance at this Mayo course does not indicate nor guarantee competence or proficiency in the performance of any procedures which may be discussed or taught in this course.